Advanced Medical Isotope Corporation (trading symbol QB:ADMD)
1021 N. Kellogg St. Kennewick, Washington 99336 US
T: 509.736.4000 F: 509.736.4007 E: info@isotopeworld.com

Tags

Latest News

Advanced Medical Isotope CEO Releases Shareholder Letter Outlining New Streamlined Path to FDA Submission

(Tue, 14, Feb 2017) >> read more

 

Advanced Medical Isotope CEO Issues Letter to Shareholders Issues Full Status Update, Planned FDA Submission Pathway and Business Plan for 2017 and Beyond

(Wed, 11, Jan 2017) >> read more

 

Advanced Medical Isotope announced today that Dr. Michael Korenko, Ph. D., who formerly served as an advisor to the Board, was named as AMI's interim President and Chief Executive Officer, replacing James Katzaroff.

(Tue, 20, Dec 2016) >> read more

 

Advanced Medical Isotope announced today that it has been awarded in the Superior Court of the State of Washington in and for Benton County, a total judgment of $527,875.74 USD. 
(Fri, 2, Dec 2016) >> read more

 

 Click here for more news and updates

Social Media


Wed

30

Nov

2016

Advanced Medical Isotope to Present at the 9th Annual LD Micro Main Event

KENNEWICK, WA / ACCESSWIRE / November 30, 2016 / Advanced Medical Isotope Corporation ("AMI") (OTC PINK: ADMD), a late stage radiation oncology focused medical device company, announced today that it will be presenting at the 9th annual LD Micro Main Event on Tuesday, December 6th at 9 AM PST / 12 PM EST at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.

 

CEO, Chairman and Founder, James Katzaroff will be presenting, as well as meeting with investors on Tuesday, December 6th as well as Wednesday, December 7th. All interested parties are kindly asked to schedule a private meeting through the conference meeting system.

 

The LD Micro Main Event is the largest independent conference for small/microcap companies and will feature 240 presenting names.

 

View Advanced Medical Isotope's profile here: http://www.ldmicro.com/profile/ADMD

 

To review a copy of Advanced Medical Isotope's Investor deck, click here: ADMD Investor Deck

 

News Compliments of Accesswire.

 

About Advanced Medical Isotope Corporation

 

Advanced Medical Isotope Corporation (ADMD) is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for the treatment of non resectable tumors. The IsoPet Solutions division is focused on establishing the infrastructure necessary to provide product to veterinary clinics, including regulatory clearances and compliance, as well as providing product awareness and education to veterinary oncologists. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The Company intends to outsource material aspects of manufacturing, distribution, sales, and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans. For more information, please visit our websites: www.isopetsolutions.com and www.isotopeworld.com.

 

The LD Micro Main Event is the largest independent conference for small/microcap companies and will feature 240 presenting names.

 

About LD Micro

 

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe. 

 

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com/events for more information.

 

Safe Harbor Statement

 

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.

 

CONTACT:

 

Company Contact:

Advanced Medical Isotope Corporation

James C. Katzaroff, CEO

1021 N Kellogg 

Kennewick WA 99336

509-736-4000

 

Investors:

Circadian Group IR

Tyler Troup, B. Comm

info@Circadian-group.com

877-950-8300

 

SOURCE: Advanced Medical Isotope Corporation via LD Micro